company background image
2VJ logo

Ascletis Pharma DB:2VJ Stock Report

Last Price

€0.18

Market Cap

€191.1m

7D

-3.3%

1Y

-41.8%

Updated

21 Mar, 2024

Data

Company Financials +

2VJ Stock Overview

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally.

2VJ fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Ascletis Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Ascletis Pharma
Historical stock prices
Current Share PriceHK$0.18
52 Week HighHK$0.31
52 Week LowHK$0.14
Beta0.66
1 Month Change-16.04%
3 Month Change17.88%
1 Year Change-41.83%
3 Year Change-40.27%
5 Year Change-76.88%
Change since IPO-84.52%

Recent News & Updates

Recent updates

Shareholder Returns

2VJDE BiotechsDE Market
7D-3.3%0.06%0.07%
1Y-41.8%28.6%4.9%

Return vs Industry: 2VJ underperformed the German Biotechs industry which returned 28.6% over the past year.

Return vs Market: 2VJ underperformed the German Market which returned 4.9% over the past year.

Price Volatility

Is 2VJ's price volatile compared to industry and market?
2VJ volatility
2VJ Average Weekly Movement11.9%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.5%

Stable Share Price: 2VJ has not had significant price volatility in the past 3 months.

Volatility Over Time: 2VJ's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
2013243Jinzi Jason Wuhttps://www.ascletis.com

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis.

Ascletis Pharma Inc. Fundamentals Summary

How do Ascletis Pharma's earnings and revenue compare to its market cap?
2VJ fundamental statistics
Market cap€191.13m
Earnings (TTM)-€30.99m
Revenue (TTM)€7.94m

24.1x

P/S Ratio

-6.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2VJ income statement (TTM)
RevenueCN¥62.38m
Cost of RevenueCN¥72.82m
Gross Profit-CN¥10.44m
Other ExpensesCN¥232.97m
Earnings-CN¥243.40m

Last Reported Earnings

Jun 30, 2023

Next Earnings Date

Mar 25, 2024

Earnings per share (EPS)-0.24
Gross Margin-16.74%
Net Profit Margin-390.21%
Debt/Equity Ratio0%

How did 2VJ perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.